Current technological development of antibody therapeutics

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 21-32

  Yamaguchi, Ayami ^a   Usami, Katsuaki ^a   Masuda, Kazuhiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

ADCC; Afucosylated antibody; Amino acid mutants; Antibody; CDC; Domain exchange antibody; Effector functions; Fucose; IgG; Oligosaccharides

Indexed keywords

ADALIMUMAB; AME-133V; CD16 ANTIGEN; CD19 ANTIBODY; CD20 ANTIBODY; CD20 ANTIGEN; CETUXIMAB; CHIMERIC ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; ESSENTIAL AMINO ACID; FC RECEPTOR IIA; FC RECEPTOR IIB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; OLIGOSACCHARIDE; PERTUZUMAB; RHUMAB V114; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; BINDING AFFINITY; BIOTECHNOLOGY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; HUMAN; HYBRIDOMA; IMMUNOGENICITY; NATURAL KILLER CELL; NONHUMAN; PLASMA HALF LIFE; PROTEIN EXPRESSION; REVIEW;

EID: 79951686782     PISSN: 18715222     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152211794519458     Document Type: Review

References (87)

1. Kohler, G.; Milstein, C. Continuous cultures of fused cellssecreting antibody of predefined specificity. Nature, 1975, 256(5517), 495-497.
2. Boulianne, G.L.; Hozumi, N.; Shulman, M.J. Production offunctional chimaeric mouse/human antibody. Nature, 1984, 312(5995), 643-646.
3. Morrison, S.L.; Johnson, M.J.; Herzenberg, L.A.; Oi, V.T. Chimeric human antibody molecules: mouse antigen-bindingdomains with human constant region domains. Proc. Natl. Acad. Sci. USA, 1984, 81(21), 6851-6855.
4. Jones, P.T.; Dear, P.H.; Foote, J.; Neuberger, M.S.; Winter, G. Replacing the complementarity-determining regions in a humanantibody with those from a mouse. Nature, 1986, 321(6069), 522-525.
5. Riechmann, L.; Clark, M.; Waldmann, H.; Winter, G. Reshapinghuman antibodies for therapy. Nature, 1988, 332(6162), 323-327.
6. Verhoeyen, M.; Milstein, C.; Winter, G. Reshaping humanantibodies: grafting an antilysozyme activity. Science, 1988, 239(4847), 1534-1536.
7. Marks, J.D.; Hoogenboom, H.R.; Bonnert, T.P.; McCafferty, J.; Griffiths, A.D.; Winter, G. By-passing immunization. Humanantibodies from V-gene libraries displayed on phage. J. Mol. Biol., 1991, 222(3), 581-597.
8. Fishwild, D.M.; O'Donnell, S.L.; Bengoechea, T.; Hudson, D.V.; Harding, F.; Bernhard, S.L.; Jones, D.; Kay, R.M.; Higgins, K.M.; Schramm, S.R.; Lonberg, N. High-avidity human IgG kappamonoclonal antibodies from a novel strain of minilocus transgenicmice. Nat. Biotechnol., 1996, 14(7), 845-851.
9. Mendez, M.J.; Green, L.L.; Corvalan, J.R.; Jia, X.C.; Maynard-Currie, C.E.; Yang, X.D.; Gallo, M.L.; Louie, D.M.; Lee, D.V.; Erickson, K.L.; Luna, J.; Roy, C.M.; Abderrahim, H.; Kirschenbaum, F.; Noguchi, M.; Smith, D.H.; Fukushima, A.; Hales, J.F.; Klapholz, S.; Finer, M.H.; Davis, C.G.; Zsebo, K.M.; Jakobovits, A. Functional transplant of megabase humanimmunoglobulin loci recapitulates human antibody response inmice. Nat. Genet., 1997, 15(2), 146-156.
10. Tomizuka, K.; Yoshida, H.; Uejima, H.; Kugoh, H.; Sato, K.; Ohguma, A.; Hayasaka, M.; Hanaoka, K.; Oshimura, M.; Ishida, I. Functional expression and germline transmission of a humanchromosome fragment in chimaeric mice. Nat. Genet., 1997, 16(2), 133-143.
11. Tomizuka, K.; Shinohara, T.; Yoshida, H.; Uejima, H.; Ohguma, A.; Tanaka, S.; Sato, K.; Oshimura, M.; Ishida, I. Double transchromosomicmice: maintenance of two individual humanchromosome fragments containing Ig heavy and kappa loci andexpression of fully human antibodies. Proc. Natl. Acad. Sci. USA, 2000, 97(2), 722-727.
12. Reichert, J.M.; Rosensweig, C.J.; Faden, L.B.; Dewitz, M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol., 2005, 23(9), 1073-1078.
13. Teicher, B.A. Antibody-drug conjugate targets. Curr. Cancer DrugTargets, 2009, 9(8), 982-1004.
14. Jumbe, N.L.; Xin, Y.; Leipold, D.D.; Crocker, L.; Dugger, D.; Mai, E.; Sliwkowski, M.X.; Fielder, P.J.; Tibbitts, J. Modeling theefficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J. Pharmacokinet. Pharmacodyn., 2010, 37(3), 221-242.
15. Baeuerle, P.A.; Reinhardt, C. Bispecific T-cell engaging antibodiesfor cancer therapy. Cancer Res., 2009, 69(12), 4941-4944.
16. Bokemeyer, C. Catumaxomab--trifunctional anti-EpCAM antibodyused to treat malignant ascites. Expert Opin. Biol. Ther., 2010, 10(8), 1259-1269.
17. Natsume, A.; Niwa, R.; Satoh, M. Improving effector functions ofantibodies for cancer treatment: Enhancing ADCC and CDC. DrugDes. Devel. Ther., 2009, 3, 7-16.
18. Presta, L.G.; Shields, R.L.; Namenuk, A.K.; Hong, K.; Meng, Y.G. Engineering therapeutic antibodies for improved function. Biochem. Soc. Trans., 2002, 30(4), 487-490.
19. Clark, M.R. IgG effector mechanisms. Chem. Immunol., 1997, 65, 88-110.
20. Schumaker, V.N.; Calcott, M.A.; Spiegelberg, H.L.; Muller-Eberhard, H.J. Ultracentifuge studies of the binding of IgG ofdifferent subclasses to the Clq subunit of the first component ofcomplement. Biochemistry, 1976, 15(23), 5175-5181.
21. Bruggemann, M.; Williams, G.T.; Bindon, C.I.; Clark, M.R.; Walker, M.R.; Jefferis, R.; Waldmann, H.; Neuberger, M.S. Comparison of the effector functions of human immunoglobulinsusing a matched set of chimeric antibodies. J. Exp. Med., 1987, 166(5), 1351-1361.
22. Zuckier, L.S.; Chang, C.J.; Scharff, M.D.; Morrison, S.L. Chimerichuman-mouse IgG antibodies with shuffled constant region exonsdemonstrate that multiple domains contribute to in vivo half-life. Cancer Res., 1998, 58(17), 3905-3908.
23. Niwa, R.; Hatanaka, S.; Shoji-Hosaka, E.; Sakurada, M.; Kobayashi, Y.; Uehara, A.; Yokoi, H.; Nakamura, K.; Shitara, K. Enhancement of the antibody-dependent cellular cytotoxicity oflow-fucose IgG1 Is independent of FcgammaRIIIa functionalpolymorphism. Clin. Cancer Res., 2004, 10(18 Pt 1), 6248-6255.
24. Reddy, M.P.; Kinney, C.A.; Chaikin, M.A.; Payne, A.; Fishman-Lobell, J.; Tsui, P.; Dal Monte, P.R.; Doyle, M.L.; Brigham-Burke, M.R.; Anderson, D.; Reff, M.; Newman, R.; Hanna, N.; Sweet, R.W.; Truneh, A. Elimination of Fc receptor-dependent effectorfunctions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol., 2000, 164(4), 1925-1933.
25. Addeo, R.; Caraglia, M.; Cerbone, D.; Frega, N.; Cimmino, G.; Abbruzzese, A.; Del Prete, S. Panitumumab: a new frontier oftarget therapy for the treatment of metastatic colorectal cancer. Expert. Rev. Anticancer Ther., 2010, 10(4), 499-505.
26. Jefferis, R. Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther., 2007, 7(9), 1401-1413.
27. Jefferis, R.; Lund, J.; Pound, J.D. IgG-Fc-mediated effectorfunctions: molecular definition of interaction sites for effectorligands and the role of glycosylation. Immunol. Rev., 1998, 163, 59-76.
28. Deisenhofer, J. Crystallographic refinement and atomic models of ahuman Fc fragment and its complex with fragment B of protein Afrom Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry, 1981, 20(9), 2361-2370.
29. Rothlisberger, D.; Honegger, A.; Pluckthun, A. Domaininteractions in the Fab fragment: a comparative evaluation of thesingle-chain Fv and Fab format engineered with variable domainsof different stability. J. Mol. Biol., 2005, 347(4), 773-789.
30. Dorai, H.; Mueller, B.M.; Reisfeld, R.A.; Gillies, S.D. Aglycosylated chimeric mouse/human IgG1 antibody retains someeffector function. Hybridoma, 1991, 10(2), 211-217.
31. Wright, A.; Morrison, S.L. Effect of glycosylation on antibodyfunction: implications for genetic engineering. Trends Biotechnol., 1997, 15(1), 26-32.
32. Burmeister, W.P.; Huber, A.H.; Bjorkman, P.J. Crystal structure ofthe complex of rat neonatal Fc receptor with Fc. Nature, 1994, 372(6504), 379-383.
33. Heijnen, I.A.; van de Winkel, J.G. Human IgG Fc receptors. Int. Rev. Immunol., 1997, 16(1-2), 29-55.
34. Ravetch, J.V. Fc receptors. Curr. Opin. Immunol., 1997, 9(1), 121-125.
35. Koene, H.R.; Kleijer, M.; Algra, J.; Roos, D.; von dem Borne, A.E.; de Haas, M. Fc gammaRIIIa-158V/F polymorphisminfluences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood, 1997, 90(3), 1109-1114.
36. Dall'Ozzo, S.; Tartas, S.; Paintaud, G.; Cartron, G.; Colombat, P.; Bardos, P.; Watier, H.; Thibault, G. Rituximab-dependentcytotoxicity by natural killer cells: influence of FCGR3Apolymorphism on the concentration-effect relationship. CancerRes., 2004, 64(13), 4664-4669.
37. Cartron, G.; Dacheux, L.; Salles, G.; Solal-Celigny, P.; Bardos, P.; Colombat, P.; Watier, H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptorFcgammaRIIIa gene. Blood, 2002, 99(3), 754-758.
38. Anolik, J.H.; Campbell, D.; Felgar, R.E.; Young, F.; Sanz, I.; Rosenblatt, J.; Looney, R.J. The relationship of FcgammaRIIIagenotype to degree of B cell depletion by rituximab in thetreatment of systemic lupus erythematosus. Arthritis Rheum., 2003, 48(2), 455-459.
39. Weng, W.K.; Levy, R. Two immunoglobulin G fragment Creceptor polymorphisms independently predict response torituximab in patients with follicular lymphoma. J. Clin. Oncol., 2003, 21(21), 3940-3947.
40. Shields, R.L.; Namenuk, A.K.; Hong, K.; Meng, Y.G.; Rae, J.; Briggs, J.; Xie, D.; Lai, J.; Stadlen, A.; Li, B.; Fox, J.A.; Presta, L.G. High resolution mapping of the binding site on human IgG1for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn anddesign of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem., 2001, 276(9), 6591-6604.
41. Lazar, G.A.; Dang, W.; Karki, S.; Vafa, O.; Peng, J.S.; Hyun, L.; Chan, C.; Chung, H.S.; Eivazi, A.; Yoder, S.C.; Vielmetter, J.; Carmichael, D.F.; Hayes, R.J.; Dahiyat, B.I. Engineered antibodyFc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA, 2006, 103(11), 4005-4010.
42. Stavenhagen, J.B.; Gorlatov, S.; Tuaillon, N.; Rankin, C.T.; Li, H.; Burke, S.; Huang, L.; Vijh, S.; Johnson, S.; Bonvini, E.; Koenig, S. Fc optimization of therapeutic antibodies enhances their ability tokill tumor cells in vitro and controls tumor expansion in vivo vialow-affinity activating Fcgamma receptors. Cancer Res., 2007, 67(18), 8882-8890.
43. Boyd, P.N.; Lines, A.C.; Patel, A.K. The effect of the removal ofsialic acid, galactose and total carbohydrate on the functionalactivity of Campath-1H. Mol. Immunol., 1995, 32(17-18), 1311-1318.
44. Shinkawa, T.; Nakamura, K.; Yamane, N.; Shoji-Hosaka, E.; Kanda, Y.; Sakurada, M.; Uchida, K.; Anazawa, H.; Satoh, M.; Yamasaki, M.; Hanai, N.; Shitara, K. The absence of fucose but notthe presence of galactose or bisecting N-acetylglucosamine ofhuman IgG1 complex-type oligosaccharides shows the critical roleof enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem., 2003, 278(5), 3466-3473.
45. Umana, P.; Jean-Mairet, J.; Moudry, R.; Amstutz, H.; Bailey, J.E. Engineered glycoforms of an antineuroblastoma IgG1 withoptimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol., 1999, 17(2), 176-180.
46. Schuster, M.; Umana, P.; Ferrara, C.; Brunker, P.; Gerdes, C.; Waxenecker, G.; Wiederkum, S.; Schwager, C.; Loibner, H.; Himmler, G.; Mudde, G.C. Improved effector functions of atherapeutic monoclonal Lewis Y-specific antibody by glycoformengineering. Cancer Res., 2005, 65(17), 7934-7941.
47. Shields, R.L.; Lai, J.; Keck, R.; O'Connell, L.Y.; Hong, K.; Meng, Y.G.; Weikert, S.H.; Presta, L.G. Lack of fucose on human IgG1N-linked oligosaccharide improves binding to human FcgammaRIII and antibody-dependent cellular toxicity. J. Biol. Chem., 2002, 277(30), 26733-26740.
48. Junttila, T.T.; Parsons, K.; Olsson, C.; Lu, Y.; Xin, Y.; Theriault, J.; Crocker, L.; Pabonan, O.; Baginski, T.; Meng, G.; Totpal, K.; Kelley, R.F.; Sliwkowski, M.X. Superior in vivo efficacy ofafucosylated trastuzumab in the treatment of HER2-amplifiedbreast cancer. Cancer Res., 2010, 70(11), 4481-4489.
49. Matsumiya, S.; Yamaguchi, Y.; Saito, J.; Nagano, M.; Sasakawa, H.; Otaki, S.; Satoh, M.; Shitara, K.; Kato, K. Structuralcomparison of fucosylated and nonfucosylated Fc fragments ofhuman immunoglobulin G1. J. Mol. Biol., 2007, 368(3), 767-779.
50. Ferrara, C.; Stuart, F.; Sondermann, P.; Brunker, P.; Umana, P. Thecarbohydrate at FcgammaRIIIa Asn-162. An element required forhigh affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem., 2006, 281(8), 5032-5036.
51. Masuda, K.; Kubota, T.; Kaneko, E.; Iida, S.; Wakitani, M.; Kobayashi-Natsume, Y.; Kubota, A.; Shitara, K.; Nakamura, K. Enhanced binding affinity for FcgammaRIIIa of fucose-negativeantibody is sufficient to induce maximal antibody-dependentcellular cytotoxicity. Mol. Immunol., 2007, 44(12), 3122-3131.
52. Niwa, R.; Sakurada, M.; Kobayashi, Y.; Uehara, A.; Matsushima, K.; Ueda, R.; Nakamura, K.; Shitara, K. Enhanced natural killercell binding and activation by low-fucose IgG1 antibody results inpotent antibody-dependent cellular cytotoxicity induction at lowerantigen density. Clin. Cancer Res., 2005, 11(6), 2327-2336.
53. Yamane-Ohnuki, N.; Kinoshita, S.; Inoue-Urakubo, M.; Kusunoki, M.; Iida, S.; Nakano, R.; Wakitani, M.; Niwa, R.; Sakurada, M.; Uchida, K.; Shitara, K.; Satoh, M. Establishment of FUT8knockout Chinese hamster ovary cells: an ideal host cell line forproducing completely defucosylated antibodies with enhancedantibody-dependent cellular cytotoxicity. Biotechnol. Bioeng., 2004, 87(5), 614-622.
54. Okazaki, A.; Shitara, K. Lack of fucose improves antibody effectorfunction. Seikagaku, 2005, 77(1), 45-50.
55. Teeling, J.L.; Mackus, W.J.; Wiegman, L.J.; van den Brakel, J.H.; Beers, S.A.; French, R.R.; van Meerten, T.; Ebeling, S.; Vink, T.; Slootstra, J.W.; Parren, P.W.; Glennie, M.J.; van de Winkel, J.G. The biological activity of human CD20 monoclonal antibodies islinked to unique epitopes on CD20. J. Immunol., 2006, 177(1), 362-371.
56. Cragg, M.S.; Morgan, S.M.; Chan, H.T.; Morgan, B.P.; Filatov, A.V.; Johnson, P.W.; French, R.R.; Glennie, M.J. Complementmediatedlysis by anti-CD20 mAb correlates with segregation intolipid rafts. Blood, 2003, 101(3), 1045-1052.
57. Ragupathi, G.; Liu, N.X.; Musselli, C.; Powell, S.; Lloyd, K.; Livingston, P.O. Antibodies against tumor cell glycolipids andproteins, but not mucins, mediate complement-dependentcytotoxicity. J. Immunol., 2005, 174(9), 5706-5712.
58. Di Gaetano, N.; Cittera, E.; Nota, R.; Vecchi, A.; Grieco, V.; Scanziani, E.; Botto, M.; Introna, M.; Golay, J. Complementactivation determines the therapeutic activity of rituximab in vivo. J. Immunol., 2003, 171(3), 1581-1587.
59. Coiffier, B.; Lepretre, S.; Pedersen, L.M.; Gadeberg, O.; Fredriksen, H.; van Oers, M.H.; Wooldridge, J.; Kloczko, J.; Holowiecki, J.; Hellmann, A.; Walewski, J.; Flensburg, M.; Petersen, J.; Robak, T. Safety and efficacy of ofatumumab, a fullyhuman monoclonal anti-CD20 antibody, in patients with relapsedor refractory B-cell chronic lymphocytic leukemia: a phase 1-2study. Blood, 2008, 111(3), 1094-1100.
60. Hagenbeek, A.; Gadeberg, O.; Johnson, P.; Pedersen, L.M.; Walewski, J.; Hellmann, A.; Link, B.K.; Robak, T.; Wojtukiewicz, M.; Pfreundschuh, M.; Kneba, M.; Engert, A.; Sonneveld, P.; Flensburg, M.; Petersen, J.; Losic, N.; Radford, J. First clinical useof ofatumumab, a novel fully human anti-CD20 monoclonalantibody in relapsed or refractory follicular lymphoma: results of aphase 1/2 trial. Blood, 2008, 111(12), 5486-5495.
61. Lemery, S.J.; Zhang, J.Z.; Rothmann, M.D.; Yang, J.; Earp, J.C.; Zhao, H.; McDougal, A.; Pilaro, A.; Chiang, R.; Gootenberg, J.; Keegan, P.; Pazdur, R. U.S. food and drug administration approval:ofatumumab for the treatment of patients with chronic lymphocyticleukemia refractory to fludarabine and alemtuzumab. Clin. CancerRes., 2010, 16(17), 4331-4338.
62. Golay, J.; Zaffaroni, L.; Vaccari, T.; Lazzari, M.; Borleri, G.M.; Bernasconi, S.; Tedesco, F.; Rambaldi, A.; Introna, M. Biologicresponse of B lymphoma cells to anti-CD20 monoclonal antibodyrituximab in vitro: CD55 and CD59 regulate complement-mediatedcell lysis. Blood, 2000, 95(12), 3900-3908.
63. Terui, Y.; Sakurai, T.; Mishima, Y.; Sugimura, N.; Sasaoka, C.; Kojima, K.; Yokoyama, M.; Mizunuma, N.; Takahashi, S.; Ito, Y.; Hatake, K. Blockade of bulky lymphoma-associated CD55expression by RNA interference overcomes resistance tocomplement-dependent cytotoxicity with rituximab. Cancer Sci., 2006, 97(1), 72-79.
64. Idusogie, E.E.; Wong, P.Y.; Presta, L.G.; Gazzano-Santoro, H.; Totpal, K.; Ultsch, M.; Mulkerrin, M.G. Engineered antibodieswith increased activity to recruit complement. J. Immunol., 2001, 166(4), 2571-2575.
65. Dall'Acqua, W.F.; Cook, K.E.; Damschroder, M.M.; Woods, R.M.; Wu, H. Modulation of the effector functions of a human IgG1through engineering of its hinge region. J. Immunol., 2006, 177(2), 1129-1138.
66. Moore, G.L.; Chen, H.; Karki, S.; Lazar, G.A. Engineered Fcvariant antibodies with enhanced ability to recruit complement andmediate effector functions. MAbs, 2010, 2(2).
67. Natsume, A.; In, M.; Takamura, H.; Nakagawa, T.; Shimizu, Y.; Kitajima, K.; Wakitani, M.; Ohta, S.; Satoh, M.; Shitara, K.; Niwa, R. Engineered antibodies of IgG1/IgG3 mixed isotype withenhanced cytotoxic activities. Cancer Res., 2008, 68(10), 3863-3872.
68. Natsume, A.; Shimizu-Yokoyama, Y.; Satoh, M.; Shitara, K.; Niwa, R. Engineered anti-CD20 antibodies with enhancedcomplement-activating capacity mediate potent anti-lymphomaactivity. Cancer Sci., 2009, 100(12), 2411-2418.
69. Roopenian, D.C.; Akilesh, S. FcRn: the neonatal Fc receptor comesof age. Nat. Rev. Immunol., 2007, 7(9), 715-725.
70. Roopenian, D.C.; Christianson, G.J.; Sproule, T.J.; Brown, A.C.; Akilesh, S.; Jung, N.; Petkova, S.; Avanessian, L.; Choi, E.Y.; Shaffer, D.J.; Eden, P.A.; Anderson, C.L. The MHC class I-likeIgG receptor controls perinatal IgG transport, IgG homeostasis, andfate of IgG-Fc-coupled drugs. J. Immunol., 2003, 170(7), 3528-3533.
71. Yeung, Y.A.; Leabman, M.K.; Marvin, J.S.; Qiu, J.; Adams, C.W.; Lien, S.; Starovasnik, M.A.; Lowman, H.B. Engineering humanIgG1 affinity to human neonatal Fc receptor: impact of affinityimprovement on pharmacokinetics in primates. J. Immunol., 2009, 182(12), 7663-7671.
72. Hinton, P.R.; Xiong, J.M.; Johlfs, M.G.; Tang, M.T.; Keller, S.; Tsurushita, N. An engineered human IgG1 antibody with longerserum half-life. J. Immunol., 2006, 176(1), 346-356.
73. Dall'Acqua, W.F.; Kiener, P.A.; Wu, H. Properties of human IgG1sengineered for enhanced binding to the neonatal Fc receptor(FcRn). J. Biol. Chem., 2006, 281(33), 23514-23524.
74. Petkova, S.B.; Akilesh, S.; Sproule, T.J.; Christianson, G.J.; AlKhabbaz, H.; Brown, A.C.; Presta, L.G.; Meng, Y.G.; Roopenian, D.C. Enhanced half-life of genetically engineered human IgG1antibodies in a humanized FcRn mouse model: potentialapplication in humorally mediated autoimmune disease. Int. Immunol., 2006, 18(12), 1759-1769.
75. Zalevsky, J.; Chamberlain, A.K.; Horton, H.M.; Karki, S.; Leung, I.W.; Sproule, T.J.; Lazar, G.A.; Roopenian, D.C.; Desjarlais, J.R. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol., 2010, 28(2), 157-159.
76. Cardarelli, P.M.; Moldovan-Loomis, M.C.; Preston, B.; Black, A.; Passmore, D.; Chen, T.H.; Chen, S.; Liu, J.; Kuhne, M.R.; Srinivasan, M.; Assad, A.; Witte, A.; Graziano, R.F.; King, D.J. Invitro and in vivo characterization of MDX-1401 for therapy ofmalignant lymphoma. Clin. Cancer Res., 2009, 15(10), 3376-3383.
77. Cardarelli, P.M.; Rao-Naik, C.; Chen, S.; Huang, H.; Pham, A.; Moldovan-Loomis, M.C.; Pan, C.; Preston, B.; Passmore, D.; Liu, J.; Kuhne, M.R.; Witte, A.; Blanset, D.; King, D.J. Anonfucosylated human antibody to CD19 with potent B-celldepletive activity for therapy of B-cell malignancies. CancerImmunol. Immunother., 2009, [Epub ahead of print].
78. Robak, T. GA-101, a third-generation, humanized and glycoengineeredanti-CD20 mAb for the treatment of B-cell lymphoidmalignancies. Curr. Opin. Investig. Drugs, 2009, 10(6), 588-596.
79. Kolbeck, R.; Kozhich, A.; Koike, M.; Peng, L.; Andersson, C.K.; Damschroder, M.M.; Reed, J.L.; Woods, R.; Dall'acqua, W.W.; Stephens, G.L.; Erjefalt, J.S.; Bjermer, L.; Humbles, A.A.; Gossage, D.; Wu, H.; Kiener, P.A.; Spitalny, G.L.; Mackay, C.R.; Molfino, N.A.; Coyle, A.J. MEDI-563, a humanized anti-IL-5receptor alpha mAb with enhanced antibody-dependent cellmediatedcytotoxicity function. J. Allergy Clin. Immunol., 2010, 125(6), 1344-1353. e2.
80. Suzuki, R. Dosing of a Phase I Study of KW-0761, an Anti-CCR4Antibody, for Adult T-Cell Leukemia-Lymphoma and PeripheralT-Cell Lymphoma. J. Clin. Oncol., 2010, 28(23), e404-405.
81. Manches, O.; Lui, G.; Chaperot, L.; Gressin, R.; Molens, J.P.; Jacob, M.C.; Sotto, J.J.; Leroux, D.; Bensa, J.C.; Plumas, J. In vitromechanisms of action of rituximab on primary non-Hodgkinlymphomas. Blood, 2003, 101(3), 949-954.
82. Czuczman, M.S.; Gregory, S.A. The future of CD20 monoclonalantibody therapy in B-cell malignancies. Leuk. Lymph, 2010, 51(6), 983-994.
83. Bowles, J.A.; Wang, S.Y.; Link, B.K.; Allan, B.; Beuerlein, G.; Campbell, M.A.; Marquis, D.; Ondek, B.; Wooldridge, J.E.; Smith, B.J.; Breitmeyer, J.B.; Weiner, G.J. Anti-CD20 monoclonalantibody with enhanced affinity for CD16 activates NK cells atlower concentrations and more effectively than rituximab. Blood, 2006, 108(8), 2648-2654.
84. Bello, C.; Sotomayor, E.M. Monoclonal antibodies for B-celllymphomas: rituximab and beyond. Hematol. Am. Soc. Hematol. Educ. Prog., 2007, 233-242.
85. Mossner, E.; Brunker, P.; Moser, S.; Puntener, U.; Schmidt, C.; Herter, S.; Grau, R.; Gerdes, C.; Nopora, A.; van Puijenbroek, E.; Ferrara, C.; Sondermann, P.; Jager, C.; Strein, P.; Fertig, G.; Friess, T.; Schull, C.; Bauer, S.; Dal Porto, J.; Del Nagro, C.; Dabbagh, K.; Dyer, M.J.; Poppema, S.; Klein, C.; Umana, P. Increasing theefficacy of CD20 antibody therapy through the engineering of anew type II anti-CD20 antibody with enhanced direct and immuneeffector cell-mediated B-cell cytotoxicity. Blood, 2010, 115(22), 4393-4402.
86. Chan, A.C.; Carter, P.J. Therapeutic antibodies for autoimmunityand inflammation. Nat. Rev. Immunol., 2010, 10(5), 301-316.
87. Bargou, R.; Leo, E.; Zugmaier, G.; Klinger, M.; Goebeler, M.; Knop, S.; Noppeney, R.; Viardot, A.; Hess, G.; Schuler, M.; Einsele, H.; Brandl, C.; Wolf, A.; Kirchinger, P.; Klappers, P.; Schmidt, M.; Riethmuller, G.; Reinhardt, C.; Baeuerle, P.A.; Kufer, P. Tumor regression in cancer patients by very low doses of a Tcell-engaging antibody. Science, 2008, 321(5891), 974-977.